151 related articles for article (PubMed ID: 11503012)
1. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
Shintani M; Ieiri I; Inoue K; Mamiya K; Ninomiya H; Tashiro N; Higuchi S; Otsubo K
Clin Pharmacol Ther; 2001 Aug; 70(2):175-82. PubMed ID: 11503012
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
[TBL] [Abstract][Full Text] [Related]
4. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
[TBL] [Abstract][Full Text] [Related]
5. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790
[TBL] [Abstract][Full Text] [Related]
6. [Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Ned Tijdschr Geneeskd; 2001 Feb; 145(7):312-5. PubMed ID: 11234294
[TBL] [Abstract][Full Text] [Related]
7. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green.
Hiratsuka M; Agatsuma Y; Mizugaki M
Mol Genet Metab; 1999 Nov; 68(3):357-62. PubMed ID: 10562462
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
Yilmaz N; Erbağci AB; Aynacioğlu AS
Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
10. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
[TBL] [Abstract][Full Text] [Related]
11. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
12. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
13. [Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced influenza-virus-associated encephalopathy].
Funato T; Kozawa K; Kaku M
Rinsho Byori; 2002 Feb; 50(2):140-5. PubMed ID: 11925850
[TBL] [Abstract][Full Text] [Related]
14. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
15. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Drug Metab Dispos; 2004 May; 32(5):484-9. PubMed ID: 15100169
[TBL] [Abstract][Full Text] [Related]
16. Activation of human CYP2C9 promoter and regulation by CAR and PXR in mouse liver.
Al-Dosari MS; Knapp JE; Liu D
Mol Pharm; 2006; 3(3):322-8. PubMed ID: 16749864
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of acenocoumarol pharmacodynamics.
Morin S; Bodin L; Loriot MA; Thijssen HH; Robert A; Strabach S; Verstuyft C; Tregouet DA; Dubert L; Laurent-Puig P; Funck-Brentano C; Jaillon P; Beaune PH; Becquemont L
Clin Pharmacol Ther; 2004 May; 75(5):403-14. PubMed ID: 15116053
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of genetic polymorphisms identified in the human cytochrome P450 4F12 (CYP4F12) promoter region.
Cauffiez C; Klinzig F; Rat E; Tournel G; Allorge D; Chevalier D; Lovecchio T; Pottier N; Colombel JF; Lhermitte M; D'Halluin JC; Broly F; Lo-Guidice JM
Biochem Pharmacol; 2004 Jun; 67(12):2231-8. PubMed ID: 15163554
[TBL] [Abstract][Full Text] [Related]
19. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
20. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.
Ieiri I; Tainaka H; Morita T; Hadama A; Mamiya K; Hayashibara M; Ninomiya H; Ohmori S; Kitada M; Tashiro N; Higuchi S; Otsubo K
Ther Drug Monit; 2000 Jun; 22(3):237-44. PubMed ID: 10850388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]